Format

Send to

Choose Destination
J Biomed Mater Res A. 2015 Aug;103(8):2807-14. doi: 10.1002/jbm.a.35396. Epub 2015 Feb 11.

Bone formation by human umbilical cord perivascular cells.

Author information

1
School of Dental Medicine, Tsurumi University, Tsurumi-ku, Yokohama, Kanagawa, Japan.
2
Research Center of Electron Microscopy, Tsurumi University, School of Dental Medicine, 2-1-3, Tsurumi, Tsurumi-ku, Yokohama, 230-8501, Japan.
3
Department of Periodontology, Tsurumi University, School of Dental Medicine, 2-1-3, Tsurumi, Tsurumi-ku, Yokohama, 230-8501, Japan.
4
Department of Translational Research, Tsurumi University School of Dental Medicine, 2-1-3, Tsurumi, Tsurumi-ku, Yokohama, 230-8501, Japan.
5
Faculty of Dentistry, University of Toronto, Ontario M5S, Canada.
6
University of Toronto, IBBME, Ontario M5S, Canada.

Abstract

We investigated the possibility of employing human umbilical perivascular cells (HUCPVCs) within the context of finding an alternative source of mesenchymal stromal cells (MSC) for bone tissue engineering. Since it has previously been reported that conditioned medium (CM) from osteogenic bone marrow (BM) MSCs can potentiate osteogenic differentiation in a secondary cell population, we also employed BM-MSCs to generate CM to stimulate osteogenesis in the HUCPVCs. The BM-MSCs were a commercially available immortalized human cell line. In vitro assays showed negligible levels of osteogenic gene expression in HUCPVCs compared to BM-MSC, but alkaline phosphatase was detected when HUCPVC were cultured in osteogenic medium in the presence of CM from BM-MSC. An in vivo assay employing a rat calvarial osteotomy defect, together with a collagen sponge scaffold, showed that HUCPVCs provided statistically significant bony repair compared to controls. BM-MSC loaded scaffolds were not statistically different from either controls or HUCPVCs. The addition of BM-MSC CM to HUCPVCs also produced no statistically significant difference to the bone formed by HUCPVCs alone. Our results demonstrate that the in vitro assays employed did not predict in vivo outcomes, and that the BM-MSC cell line employed, or CM from such cells, provided no osteogenic advantage over the use of HUCPVCs alone.

KEYWORDS:

bone; bone marrow cell line; osteotomy model; perivascular cells; umbilical cord

PMID:
25676366
DOI:
10.1002/jbm.a.35396
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center